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Abstract
Introduction Neurocutaneous melanosis (NCM) is a sporadic condition characterised by congenital melanocytic nevi and
melanocytic thickening of the leptomeninges. It is believed to result from congenital dysplasia of melanin-producing cells within
the skin and leptomeninges. The management of cutaneous manifestations remains controversial; for neurological manifesta-
tions, outcome remains poor even with the use of radiotherapy and chemotherapy.
Patients and methods We describe the case of a 5-month-old boy who presented with giant congenital melanocytic nevus and
hydrocephalus. MR imaging and CSF immunohistochemistry confirmed leptomeningeal melanosis. We discuss the diagnosis,
treatment and prognosis of this rare disorder in the light of recent published literature.
Results Patient required placement of right-sided ventriculoperitoneal shunt to control hydrocephalus. The patient tolerated the
procedure well and was discharged home with normal neurological function. A presumptive diagnosis of NCMwas made based
on the MR characteristics, CSF cytology and clinical presentation. He received trametinib, a MAPK/Erk kinase inhibitor for
7 months. At 30 months of age, he developed left-sided weakness and status epilepticus requiring paediatric intensive care unit
admission and ventilator support. The patient eventually succumbed to malignant transformation of leptomeningeal disease.
Conclusion Cutaneous manifestations of NCM are usually congenital, and neurological manifestations develop early in life.
Patients with large or multiple congenital nevi should therefore be investigated early to facilitate treatment. MR imaging is the
investigation of choice which can further assist in performing biopsy. Symptomatic NCM is refractory to radiotherapy and
chemotherapy and has a poor prognosis. A multidisciplinary approach is necessary in the management of NCM patients.
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Abbreviations
NCM Neurocutaneous melanosis
CNS Central nervous system
HGF/SF Hepatocyte growth factor/scatter factor
NRAS N-type Rat Sarcoma gene
MAPK Mitogen-activated protein kinase
MEK MAPK/Erk kinase
FDA The Food and Drug Administration
CSF Cerebral spinal fluid
DWC Dandy–Walker complex
PET Positron emission tomography
PICU Paediatric intensive care unit
DLE Diffuse leptomeningeal enhancement
Introduction
Neurocutaneous melanosis (NCM) is a rare syndrome
characterised by congenital melanocytic nevi and melanocytic
thickening of the leptomeninges [32]. Although mostly spo-
radic, a few familial cases of NCM have been reported [22]. In
most cases, NCM presents with symptoms of raised intracra-
nial pressure [1]. NCM is believed to result from congenital
dysplasia of melanin-producing cells within the skin and
leptomeninges [20].
Two thirds of patients with NCM have a giant congenital
melanocytic nevus, and the remaining third have multiple
small lesions [19]. Nevi are usually present at birth, but more
may develop later in life. Almost all nevi have a lumbosacral
(bathing trunk) distribution [10].
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In the majority of cases, NCM exhibits symptoms of
raised intracranial pressure within the first 2 years of life
[20]. As in the case reported here, most cases present
with symptoms and signs of increased intracranial pres-
sure including irritability, lethargy, recurrent vomiting,
increased head circumference, bulging anterior fontanelle
and photophobia [1]. Hydrocephalus develops in two
thirds of patients.
Historical background
Although first described by Rokitanski in 1861 [31], the
term neurocutaneous melanosis was coined by van
Bogaert in 1948 [38]. The initial diagnostic criteria of
NCM included large or numerous pigmented nevi without
malignant transformation [12], which was later revised to
include malignant transformation and distant metastasis
[10]. Since its first description, 100 or so cases have been
described in the English literature [28].
NCM is a sporadic syndrome with few reported famil-
ial cases [9, 13]. Animal models of NCM have been de-
veloped. Transgenic mice overexpressing hepatocyte
growth factor/scatter factor (HGF/SF) demonstrate exten-
sive pigmented nevi in both skin and leptomeninges of
the central nervous system, thus resembling human NCM.
HGF/SF are growth factors that control the proliferation
of neural crest melanocytes during embryogenesis [37].
Dysregulation of these growth factors may explain associated
cystic malformations of the posterior fossa such as the
Dandy–Walker complex (DWC) [37].
Oncogenic missense mutations (affecting the NRAS
gene) have been identified in affected neural and cutane-
ous tissue in NCM patients. However, these mutations
were not found in unaffected tissues and blood. The mu-
tations are thought to be the result of somatic mosaicism,
which occurs in a progenitor cell in the developing neu-
ral crest or neuroectoderm [21]. This suggests that these
mutations would be lethal if they occurred in germ line
cells [21].
The resultant phenotype is dependent upon the type of
mutation, affected cells and timing [15]. NRAS mutations
have only been found in benign melanocytic nevi. This
indicates that they are of themselves insufficient for malig-
nant transformation to occur. Given that malignant trans-
formation is an indicator of poor prognosis in NCM (as
discussed in prognosis and outcomes), a better understand-
ing of molecular genetic pathogenesis is required [39].
NRAS mutations could represent a potential therapeutic
target for NCM [27]. NRAS melanomas are thought to
proliferate through the MAPK pathway which could be
inhibited by MEK inhibitors. Trametinib for example, a
MEK inhibitor, has been approved by The Food and
Drug Administration (FDA) for the treatment of certain
NRAS-mutated melanomas [18].
The histopathological patterns of NCM cutaneous le-
sions are indistinguishable from those seen in congeni-
tal melanocytic nevi without CNS involvement. Nevus
cells spread into the dermis and encircle nerves and
blood vessels [19, 26]. Leptomeningeal melanosis is
most evident in areas of physiological melanin distribu-
tion such as the base of the brain, the ventral surface of
the pons, cerebral peduncles, the medulla and cerebel-
lum [10]. Several features have been identified to dis-
tinguish meningeal melanosis from melanoma which
can develop in about half of the cases [30]. Necrosis,
invasion of basal lamina and cell atypia can distinguish
melanoma from melanosis. Although the prognostic sig-
nificance of this distinction is unclear [20], CSF cytol-
ogy is used to investigate malignancy but its sensitivity
is reported to be around 40% [20].
Clinical presentation
A large congenital melanocytic nevus with bathing trunk
distribution is observed in two thirds of patients with
NCM [19]. In the remaining third of patients, multiple
smaller melanocytic nevi without a single large lesion
are found. Nevi are dark pigmented lesions circumscribed
with irregular borders that can be raised or flat. They are
usually present at birth, although new nevi can develop
later in life [6].
Most patients exhibit neurological symptoms by 2 years
of age; however, some cases may present during the sec-
ond or third decade of life [20]. Two thirds of patients
will present with neurological signs and symptoms due to
increased intracranial pressure such as irritability, lethar-
gy, headache, vomiting, photophobia, papilledema bulg-
ing anterior fontanel and enlarging head circumference
[1], as in our exemplary case. Seizures, aphasia and mo-
tor or cranial nerve palsies may develop in patients with
intracranial melanocytic tumours (see Table 1) [19].
Patients who present late in life may have spinal involve-
ment which may result in myelopathy, radiculopathy and
bowel or bladder dysfunction [19].
We reviewed the literature by searching PubMed using the
terms Bneurocutaneous melanosis^ and Bhydrocephalus.^ We
included only publications in English dated 01/01/2000 to
present as illustrated in Table 1.
Neurocutaneous melanosis can be linked to other
neurocutaneous disorders, such as neurofibromatosis type 1
and Sturge–Weber syndrome [10].
The association of Dandy-Walker Syndrome and NCM is a
rare complex, and to our knowledge only 24 cases have been
reported up do date [5, 11, 20, 26].
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DWC may be due to the leptomeningeal anomalies of
NCM, which could hinder the normal development of the
cerebellum and IV ventricle [19]. Two theories have been
proposed to explain the link between leptomeningeal
melanosis and DWC. Chalpouka et al. [5] suggest that
leptomeningeal melanosis restricts the ability of primitive
meningeal cells from inducing normal deposition of the
extracellular matrix, neuronal migration and formation of
CSF resorption pathways, resulting in the formation of
posterior fossa cysts and vermian aplasia characteristic of
DWC. Barkovich et al. [4], on the other hand, have pro-
posed that leptomeningeal melanosis interferes with nor-
mal ectodermal–mesodermal interaction, causing abnormal
formation of the cerebellum and fourth ventricle.
Diagnosis
Criteria for the diagnosis of NCM were first proposed in
1972 and included large or numerous pigmented nevi in
patients without malignant transformation in cutaneous le-
sions and without evidence of melanoma except in the
leptomeninges [12].
Since then, both malignant transformation of cutaneous
nevi and distant metastases of leptomeningeal melanoma
have been recorded [10]. This led to revision of the diag-
nostic criteria which currently comprise (1) large (diameter
more than 20 cm in adults or 6–9 cm in infants) or numer-
ous (three or more lesions) congenital nevi in association
with leptomeningeal melanosis or melanoma; (2) no evi-
dence of cutaneous melanoma, except in patients with his-
tologically benign meningeal lesions; and (3) no evidence
of meningeal melanoma, except in patients with histologi-
cally benign cutaneous lesions [19].
Confirmation of the diagnosis is still based on histological
findings, often only at autopsy. Hairy nevi can also be found in
up to 40% of cases of primary malignant melanoma of the
leptomeninges [2]. In rare cases of leptomeningeal
melanomatosis, tumour cells may be amelanotic (unpigmented)
and patient may not present with NCM [36]. This highlights the
difficulty of obtaining an histological diagnosis in these
conditions.
On the other hand, MR imaging may allow a presump-
tive diagnosis of CNS melanosis to be made [13, 22].
Leptomeningeal melanosis demonstrates a distinctive
hyperintensity on T1-weightedMR images and a hypointensity
on T2-weighted MR images [4, 10]. Patients may also
present with intraparenchymal lesions without meningeal
involvement [32].
Management
For cutaneous manifestations, the management remains con-
troversial. Some dermatologists support prophylactic surgical
excision of large melanocytic nevi to reduce the risk of ma-
lignant transformation, which occurs in 5 to 15% of patients
[19], and to improve cosmetic appearance. For neurological
manifestations, outcome remains poor even with the use of
radiotherapy and chemotherapy [7, 23]. Early neurosurgical
intervention, however, can assist in tissue diagnosis and has
the potential to effect early decompression [13]. The usual
surgical intervention is shunt insertion with a filter to prevent
potential seeding into the abdominal space [29].
Prognosis and outcomes
Prognosis in NCM is generally poor, with half of patients
dying within 3 years of the onset of neurological symptoms
[19]. However, the course of asymptomatic patients is var-
iable and unpredictable [14, 20]. The worst prognosis is
seen in NCM patients with Dandy–Walker complex
(DWC). DWC is thought to be a marker of melanocytic
Fig. 1 Giant hairy nevus in
bathing trunk distribution
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infiltration into the CNS and confers an increased risk for
malignant transformation [5].
Exemplary case description
A 5-month-old male was delivered via caesarean section at
36-week gestational age. At birth, two extensive congenital
hairy nevi had been observed; the first is a giant hairy nevus in
bathing trunk distribution and the second 1 cmwide on the left
upper back. Figure 1 illustrates the bathing trunk distribution
of the giant nevus.
There were no issues with his feeding, weight gain or neu-
rological development. At 5 months, he presented with a 5-
day history of drowsiness, poor feeding, high pitched cry,
nausea and vomiting.
His skin was dry and flaky. His mother had mild psoriasis
(elbows and knees) and benign moles, but there was no other
relevant family history. At the time of presentation, he was
alert but irritable, and his anterior fontanel was full and tense.
Downward gaze (Bsetting-sun^ sign) was also noticed inter-
mittently but there was no neck rigidity. A non-enhanced
computerised tomography (CT) scan demonstrated communi-
cating hydrocephalus and significant transependymal oedema,
as illustrated in Fig. 2.
An emergency right ventriculoperitoneal shunt was per-
formed. The patient recovered well from the procedure and
was discharged home on postoperative day one. The CSF
was xanthochromic and cytological examination revealed
medium-sized epithelioid non-pigmented cells with oval
nuclei and relatively high nuclear cytoplasmic ratios.
Such appearances have been described in children with
NCM [22, 29]. Immunohistochemistry highlighted
scattered lymphoid cells (CD45) and epithelioid cells were
negative for melanomamarkers (MelC, HMB45) as illustrated
in Fig. 3.
MR imaging demonstrated meningeal enhancement in the
periphery of the left and right cerebellum as well as in the
thoracic spine and conus suggestive of melanin deposition.
A presumptive diagnosis of NCM was made based on the
MR characteristics, CSF cytology and clinical presentation.
Follow-up MR 5 months after the procedure showed decom-
pressed ventricles with oedema over the thalamus and diffuse
Fig. 2 Axial CT. a
Communicating hydrocephalous
and transependymal oedema. b
Decompressed ventricles after
shunt placement
Fig. 3 CSF cytology showing medium-sized epithelioid non-pigmented
cells with oval nuclei and relatively high nuclear cytoplasmic ratios
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enhancement over the spinal cord again in keeping with CNS
melanosis, as illustrated in Fig. 4.
At 19 months of age, a repeat MRI showed arachnoid
loculations at the ventricular outflow formina as well as tha-
lamic oedema and diffuse spinal enhancement in keeping with
NCM. Skin and leptomeningeal biopsies were subsequently
taken at 21 months of age which showed N-type Rat Sarcoma
gene (NRAS)-mutated melanoma, although PETscan showed
no hypermetabolic foci within brain, spine or upper half of the
body. For 7 months, he received trametinib, a MAPK/Erk
kinase (MEK) inhibitor which inhibits cellular proliferation.
During this time, he continued to develop normally and was
attaining appropriate social and motor milestones. At
30months of age, he developed left-sided weakness and status
epilepticus requiring PICU admission and ventilator support.
No acute changes were demonstrated on head and spine CT.
He was extubated successfully but continued to deteriorate
neurologically. He received palliative treatment and died at
the age of 32 months.
Conclusions
NCM is a rare syndrome characterised by congenital
melanocytic nevi and melanocytic thickening of the
leptomeninges. Cutaneous manifestations of NCM are usually
congenital, and neurological manifestations develop early in
life. Patients with large ormultiple congenital nevi should there-
fore be investigated early—even in the absence of neurological
manifestations—to facilitate treatment plan and prognosis.
Because of the uncertain value of CSF cytology, MR imaging
is the investigation of choice especially if biopsy cannot be
carried out. As in the case reported here, symptomatic
NCM usually presents with increased intracranial pressure
and hydrocephalus and requires ventriculoperitoneal shunt
insertion. Symptomatic NCM is refractory to radiotherapy
and chemotherapy and has a poor prognosis. A multidisci-
plinary approach is necessary in the management of NCM
patients. This should include routine neurodevelopmental
assessments and dermatologist input.
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